The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
Open accessAbstract
The ability of interleukin (IL)-12 to prevent tumors when administered to individuals with a genetic risk of cancer was studied in two lines of transgenic mice expressing rat HER-2/neu oncogene in the mammary gland. Female BALB/c (H-2d) mice carrying the activated HER-2/ neu oncogene show no morphological abnormalities of the mammary gland until 3 wk of age. They then progress through atypical hyperplasia to in situ lobular carcinoma and at 33 wk of age all 10 mammary glands display invasive carcinomas. Adult FVB mice (H-2q) carrying the HER-2/neu protooncogene develop mammary carcinomas with a longer latency (38-49 wk) and a lower multiplicity (mean of 2.6 tumors/mice). Treatment with IL-12 (5 daily intraperitoneal injections, 1 wk on, 3 wk off; the first course with 50 ng IL-12/day, the second with 100 ng IL-12/day) begun at 2 wk of age in BALB/c mice and at 21 wk of age in FVB mice markedly delayed tumor onset and reduced tumor multiplicity. Analogous results were obtained in immunocompetent and permanently CD8+ T lymphocyte–depleted mice. In both transgenic lines, tumor inhibition was associated with mammary infiltration of reactive cells, production of cytokines and inducible nitric oxide synthase, and reduction in microvessel number, in combination with a high degree of hemorrhagic necrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Stuehr, D. J., & Nathan, C. F. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.169.5.1543 · Cited by 1,744
Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., & Taniguchi, M. (1997) · Science · doi:10.1126/science.278.5343.1623 · Cited by 1,237
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
Shih, C., Padhy, L. C., Murray, M., & Weinberg, R. A. (1981) · Nature · doi:10.1038/290261a0 · Cited by 791
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
Sgadari, C., Angiolillo, A., & Tosato, G. (1996) · Blood · doi:10.1182/blood.v87.9.3877.bloodjournal8793877 · Cited by 469
Halting angiogenesis suppresses carcinoma cell invasion
Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., & Fusenig, N. E. (1997) · Nature Medicine · doi:10.1038/nm1197-1222 · Cited by 420
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.
Luster, A. D., & Leder, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1057 · Cited by 407
Human Mig chemokine: biochemical and functional characterization.
Liao, F., Rabin, R. L., Yannelli, J. R., Koniaris, L. G., Vanguri, P., & Farber, J. M. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1301 · Cited by 373
Vecchi, A., Garlanda, C., Lampugnani, M. G., Resnati, M., Matteucci, C., Stoppacciaro, A., Schnürch, H., Risau, W., Ruco, L., & Mantovani, A. (1994) · PubMed · Cited by 301
Mig, the Monokine Induced By Interferon-γ, Promotes Tumor Necrosis In Vivo
Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., Burd, P. R., Yao, L., Gupta, G., Kanegane, C., & Tosato, G. (1997) · Blood · doi:10.1182/blood.v89.8.2635 · Cited by 246
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.
Drebin, J. A., Link, V. C., Weinberg, R. A., & Greene, M. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.23.9129 · Cited by 233
Cavallo, F., Giovarelli, M., Forni, G., Signorelli, P., Musiani, P., Modesti, A., Brunda, M. J., & Colombo, M. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1049 · Cited by 171
Self-citationCytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12
Tannenbaum, C. S., Wicker, N. B., Armstrong, D., Tubbs, R., Finke, J. H., Bukowski, R. M., & Hamilton, T. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.2.693 · Cited by 155
Oncogenic proteins as tumor antigens
Disis, M. L. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80079-3 · Cited by 154
Activated neu Induces Rapid Tumor Progression
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7673 · Cited by 145
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.
Noguchi, Y., Jungbluth, A., Richards, E. C., & Old, L. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11798 · Cited by 143
EGF Receptor and erb B-2 Tyrosine Kinase Domains Confer Cell Specificity for Mitogenic Signaling
Fiore, P. P. D., Segatto, O., Taylor, W. G., Aaronson, S. A., & Pierce, J. H. (1990) · Science · doi:10.1126/science.2181668 · Cited by 137
Martinotti, A., Stoppacciaro, A., Vagliani, M., et al. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250124 · Cited by 122
Vagliani, M., Rodolfo, M., Cavallo, F., Parenza, M., Melani, C. C., Parmiani, G., Forni, G., & Colombo, M. P. (1996) · PubMed · Cited by 80
Self-citationGiovarelli, M., Santoni, A., Jemma, C., Musso, T., Giuffrida, A. M., Cavallo, G., Landolfo, S., & Forni, G. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.8.2831 · Cited by 70
Self-citationWigginton, J. M., Kuhns, D. B., Back, T. C., Brunda, M. J., Wiltrout, R. H., & Cox, G. W. (1996) · PubMed · Cited by 68
Cited by
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Systemic Spread Is an Early Step in Breast Cancer
Hüsemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., Forni, G., Eils, R., Fehm, T., Riethmüller, G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.003 · Cited by 1,188
Self-citationInterleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Self-citationCretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A., Glimcher, L., et al. (2010) · Nature · doi:10.1038/nature09387 · Cited by 592
Metadata
- Authors
- Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M., Rossi, I., Nanni, P., De Giovanni, C., Bouchard, P., Wolf, S., Modesti, A., Musiani, P., Lollini, P. L., Colombo, M. P., & Forni, G.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-08-03
- Volume
- 188
- Issue
- 3
- Pages
- 589-596
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2116094134
- Cited by
- 302
- References
- 25
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.